trending Market Intelligence /marketintelligence/en/news-insights/trending/uxvhtmrrsmm2pkcuzpyr4q2 content esgSubNav
In This List

Akebia Therapeutics plans $85M common stock offering

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Akebia Therapeutics plans $85M common stock offering

Akebia Therapeutics Inc. plans to sell $85 million of its common shares in an underwritten public offering.

The company also plans to give the underwriter an option to buy up to an additional $12.8 million of shares.

Akebia plans to use the net proceeds for the continued clinical development and optimization of the vadadustat program, including pre-commercial planning activities, and the remainder for working capital, business development and other general corporate purposes.

Morgan Stanley is acting as sole book-running manager for the offering.